Novel role of hematopoietic stem cells in immunologic rejection of malignant gliomas
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Novel role of hematopoietic stem cells in immunologic rejection of malignant gliomas
Authors
Keywords
-
Journal
OncoImmunology
Volume 4, Issue 3, Pages e994374
Publisher
Informa UK Limited
Online
2015-01-23
DOI
10.4161/2162402x.2014.994374
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors
- (2014) Alena Gros et al. JOURNAL OF CLINICAL INVESTIGATION
- High-dose busulfan-thiotepa with autologous stem cell transplantation followed by posterior fossa irradiation in young children with classical or incompletely resected medulloblastoma
- (2014) Guillaume Bergthold et al. PEDIATRIC BLOOD & CANCER
- Cytokine release syndrome in cancer immunotherapy with chimeric antigen receptor engineered T cells
- (2013) Xiao-Jun Xu et al. CANCER LETTERS
- Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells
- (2013) Paul F Robbins et al. NATURE MEDICINE
- Myeloablative Temozolomide Enhances CD8+ T-Cell Responses to Vaccine and Is Required for Efficacy against Brain Tumors in Mice
- (2013) Luis A. Sanchez-Perez et al. PLoS One
- Impact of Temozolomide on Immune Response during Malignant Glioma Chemotherapy
- (2012) Sadhak Sengupta et al. Clinical & Developmental Immunology
- Blockade of Myeloid-Derived Suppressor Cells after Induction of Lymphopenia Improves Adoptive T Cell Therapy in a Murine Model of Melanoma
- (2012) K. N. Kodumudi et al. JOURNAL OF IMMUNOLOGY
- Raising the Bar: The Curative Potential of Human Cancer Immunotherapy
- (2012) S. A. Rosenberg Science Translational Medicine
- Host-Derived MCP-1 and MIP-1α Regulate Protective Anti-Tumor Immunity to Localized and Metastatic B16 Melanoma
- (2011) Yuko Nakasone et al. AMERICAN JOURNAL OF PATHOLOGY
- Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy
- (2011) S. A. Rosenberg et al. CLINICAL CANCER RESEARCH
- Personalized Cell Transfer Immunotherapy for B-Cell Malignancies and Solid Cancers
- (2011) Steven A Rosenberg et al. MOLECULAR THERAPY
- Cell transfer immunotherapy for metastatic solid cancer—what clinicians need to know
- (2011) Steven A. Rosenberg Nature Reviews Clinical Oncology
- High-dose carboplatin, thiotepa, and etoposide with autologous stem cell rescue for patients with previously irradiated recurrent medulloblastoma
- (2011) I. J. Dunkel et al. NEURO-ONCOLOGY
- Successful Treatment of Melanoma Brain Metastases with Adoptive Cell Therapy
- (2010) J. J. Hong et al. CLINICAL CANCER RESEARCH
- Do CARs Need a Driver's License? Adoptive Cell Therapy with Chimeric Antigen Receptor-Redirected T Cells Has Caused Serious Adverse Events
- (2010) Hildegard Büning et al. HUMAN GENE THERAPY
- Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2
- (2010) Richard A Morgan et al. MOLECULAR THERAPY
- Increased Intensity Lymphodepletion Enhances Tumor Treatment Efficacy of Adoptively Transferred Tumor-specific T Cells
- (2009) Claudia Wrzesinski et al. JOURNAL OF IMMUNOTHERAPY
- Chemokine CXC receptor 4-mediated glioma tumor tracking by bone marrow-derived neural progenitor/stem cells
- (2009) Q. Xu et al. MOLECULAR CANCER THERAPEUTICS
- Myeloablative chemotherapy with autologous hematopoietic progenitor cell rescue for childhood central nervous system tumors
- (2008) A Marachelian et al. BONE MARROW TRANSPLANTATION
- Hematopoietic Stem Cell–Derived Pericytic Cells in Brain Tumor Angio-Architecture
- (2008) Simon R. Bababeygy et al. STEM CELLS AND DEVELOPMENT
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started